Immunohistochemical staining of post-mortem tissues from a control patient and a ALS-FTD patient bearing a FUS p.R521C mutation (previously described by Blair et al.,3 ALS53, individual IV:5) was performed using an anti-LC3 antibody (Figure 8a). This evidence concerns the gene MAP1LC3A and amyotrophic lateral sclerosis.